Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Comment by Kabronon Aug 17, 2021 10:45pm
147 Views
Post# 33721856

RE:RE:Few Questions

RE:RE:Few QuestionsFrustrating for sure... he did say there is a queue of patients for when they decide to start. The smart thing is to do is to issue a press release on when the testing has started and revenue should rocket from there. I think we were expecting covid revenues to drop but he did mention a few more covid revenue streams to expect. There are still millions of antivaxxers out there who would prefer to pay for a test when travelling/concerts etc..than get the shot. I do agree with 1 year comment...mostly because he was preaching instant revenue with the rollout of Aristotle and decided to do it the long way too last minute. I do feel it is the best way to roll out Aristotle however he fked up with the lack of transparency which causes insecurity for an investor. I still feel the company still has huge potential and will slowly average down lol. Anyways GL ppl. #fukthebashers
<< Previous
Bullboard Posts
Next >>